शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

ANUHPHRNSEAnuh Pharma Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Wed, 20 May, 2026 · 23:52 IST

Anuh Pharma Limited has informed the Exchange regarding 'Appointment Of Scrutinizer For The 66Th Annual General Meeting.'.

Negative operating cash flowResults View source PDFExplain this filing

ANUHPHR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-6.1%Reaction day
₹81.50
prior close
₹80.81
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.1%-7.2% vs market
Pharmaceuticals peers, median of 160sector+0.2%-6.3% vs sector

On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-3.5
10m
-3.5
15m
-4.3
30m
-4.6
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-6.1+1.1-7.2+0.2-6.3
Next day
-6.2+1.2-7.4+0.2-6.4
2d
-6.3+2.8-9.1+1.5-7.8
3d
-6.1+3.5-9.7+1.4-7.6
4d
-6.1+3.5-9.6+1.6-7.7
5d
-6.1+2.8-9.0+1.0-7.2
1w
-7.5+2.8-10.3+0.4-7.9
15d
-2.5+4.2-6.7+0.7-3.2
1m
-3.2+10.1-13.3+3.1-6.3
2m
-1.4+10.0-11.4+7.2-8.6
3m
-6.3+14.6-20.8+8.2-14.4
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anuh Pharma Limited reported FY26 results with revenue from operations of Rs. 77,166 Lakhs, up 16.6% from Rs. 66,151 Lakhs in FY25. However, profit after tax declined 13.3% to Rs. 4,105 Lakhs from Rs. 4,735 Lakhs. EBITDA margin compressed significantly from 10.64% to 8.56%, a drop of 208 basis points. The board recommended a dividend of Rs. 1.50 per share (30% payout). Operating cash flow turned negative at Rs. 301 Lakhs compared to positive Rs. 3,712 Lakhs in FY25, indicating working capital pressure with inventories nearly doubling to Rs. 14,776 Lakhs. Nine promoter group shareholders holding 0.95% stake requested reclassification to public category. The company also appointed new internal auditors and a quality head.

Likely market impact

Despite revenue growth, the stock may face pressure due to declining profitability, margin compression, and negative operating cash flow. The dividend recommendation provides some support for shareholders.

By the numbersStandalone · Q4 FY26 vs Q4 FY25
Q4 FY26Q4 FY25Change
Revenue₹202.1 Cr₹198.1 Cr+2.0%
Operating profit₹16.77 Cr₹15.88 Cr+5.6%
Profit after tax₹11.68 Cr₹12.46 Cr−6.2%
EBITDA margin9.8%9.4%+0.4 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.